Pharmaceutical composition
AssigneeKyowa Kirin Co., Ltd.
InventorsHiroki Haniuda, Sachiko Enokizono, Tomoyuki Nakazato, Takuya Tokuda, Norie Fujiki
Life of this patent
Estimating the term…
Abstract
The present invention relates to a therapeutic agent for an ophthalmic disease comprising a vascular endothelial growth factor (VEGF) receptor inhibitor or an epidermal growth factor (EGF) receptor inhibitor in a nanoparticle form, having a property to be retained in a posterior eye tissue when systemically administered.
Claims33
Eye drops comprising a vascular endothelial growth factor (VEGF) receptor inhibitor in a nanoparticle form, wherein the VEGF receptor inhibitor is a compound represented by formula (II):
- or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate of the compound or the salt, and
- the VEGF receptor inhibitor has a mean particle size of 400 nm or smaller.
A freeze-dried product for producing eye drops, wherein
- the freeze-dried product comprises a vascular endothelial growth factor (VEGF) receptor inhibitor in a nanoparticle form,
- the VEGF receptor inhibitor is a compound represented by formula (II):
- or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate of the compound or the salt, and
- the VEGF receptor inhibitor has a mean particle size of 400 nm or smaller.
A method for producing eye drops, comprising dispersing a freeze-dried product into a dispersion media, wherein
- the freeze-dried product comprises a vascular endothelial growth factor (VEGF) receptor inhibitor in a nanoparticle form,
- the VEGF receptor inhibitor is a compound represented by formula (II):
- or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate of the compound or the salt, and
- the VEGF receptor inhibitor has a mean particle size of 400 nm or smaller.
A freeze-dried product for producing eye drops, wherein
- the freeze-dried product comprises a vascular endothelial growth factor (VEGF) receptor inhibitor,
- the VEGF receptor inhibitor is a compound represented by formula (II):
- or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate of the compound or the salt,
- the VEGF receptor inhibitor in the eye drops produced from the freeze-dried product is in a nanoparticle form, and
- the VEGF receptor inhibitor has a mean particle size of 400 nm or smaller.
A method for producing eye drops, comprising dispersing a freeze-dried product into a dispersion media, wherein
- the freeze-dried product comprises a vascular endothelial growth factor (VEGF) receptor inhibitor,
- the VEGF receptor inhibitor is a compound represented by formula (II):
- or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate of the compound or the salt,
- the VEGF receptor inhibitor in the eye drops produced from the freeze-dried product is in a nanoparticle form, and
- the VEGF receptor inhibitor has a mean particle size of 400 nm or smaller.
A vascular endothelial growth factor (VEGF) receptor inhibitor in a nanoparticle form for the treatment of an ophthalmic disease, wherein the VEGF receptor inhibitor is a compound represented by formula (II):
- or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate of the compound or the salt, and
- the VEGF receptor inhibitor has a mean particle size of 400 nm or smaller.
Dependencies are inferred from the claim text.